Table 3:
Incremental economic analysis estimates (US$2019) for different immunization options for different policy options by World Bank Income Levels (2019–2029)
| Vaccine policy | Incremental financial costs (US$2019 billions) | Paralytic polio cases prevented | ICER comparator threshold ($/DALY) | Incremental cost-effectiveness ratio (ICER) | Incremental net benefits (INBs) (US$201 | ||
|---|---|---|---|---|---|---|---|
| Health opportunity cost approximation | Assuming 1 GNI per capita per DALY | Per polio case (US$2019/case) | Per polio case (US$2019/DALY) | ||||
| tOPVRISIA vs. RC2 | |||||||
| LI | −1.1 | 10,024 | 173 | 866 | CSLS | CSLS | 1.2 |
| LMI | −0.2 | 12,802 | 462 | 2,310 | CSLS | CSLS | 0.6 |
| UMI | 0.5 | 1,383 | 5,484 | 9,140 | 321,624 | 321,624 | −0.3 |
| Total | −0.8 | 24,209 | NA | NA | NA | NA | 1.5 |
| tOPVRI vs. RC2 | |||||||
| LI | −1.3 | 7,341 | 173 | 866 | CSLS | CSLS | 1.4 |
| LMI | −2.3 | −4,935 | 462 | 2,310 | CSLC | CSLC | 2.1 |
| UMI | 0.5 | 1,077 | 5,484 | 9,140 | 417,289 | 417,289 | −0.4 |
| Total | −3.0 | 3,484 | NA | NA | NA | NA | 3.1 |
| 2IPV2025 vs. RC2 | |||||||
| LI | 0.1 | 4,018 | 173 | 866 | 28,564 | 28,564 | −0.1 |
| LMI | 0.4 | 6,295 | 462 | 2,310 | 55,870 | 55,870 | −0.2 |
| UMI | −0.1 | 465 | 5,484 | 9,140 | CSLS | CSLS | 0.2 |
| Total | 0.4 | 10,778 | NA | NA | NA | NA | −0.1 |
| RC2noRestarts vs. RC2 | |||||||
| LI | 0.1 | −1,513 | 173 | 866 | dominated | dominated | −0.2 |
| LMI | 0.2 | 380 | 462 | 2,310 | 557,565 | 557,565 | −0.2 |
| UMI | −0.3 | 1,707 | 5,484 | 9,140 | CSLS | CSLS | 0.6 |
| Total | 0.1 | 574 | NA | NA | NA | NA | 0.2 |
| Vaccine policy | Incremental financial costs (US$2019 billions) | Paralytic polio cases prevented | ICER comparator threshold ($/DALY) | Incremental cost-effectiveness ratio (ICER) | Incremental net benefits (INBs) (US$201 | ||
| Health opportunity cost approximation | Assuming 1 GNI per capita per DALY | Per polio case (US$2019/case) | Per polio case (US$2019/DALY) | ||||
| 1IPV2025 vs. RC2* | |||||||
| LI | −0.5 | −634 | 173 | 866 | CSLC | CSLC | 0.4 |
| LMI | −1.0 | −4,635 | 462 | 2,310 | CSLC | CSLC | 0.8 |
| UMI | −0.0 | 9 | 5,484 | 9,140 | CSLS | CSLS | 0.0 |
| Total | −1.4 | −5,260 | NA | NA | NA | NA | 1.3 |
Abbreviations CSLC, cost-saving, life-costing; CSLS, cost-saving, life-saving; cVDPV#, circulating vaccine-derived poliovirus of serotype #; DALY, disability-adjusted life-year; HI, high-income; IPV, inactivated poliovirus vaccine; LI, low-income; LMI, lower middle-income; NA, not-applicable; OPV, oral poliovirus vaccine; OPV#, OPV containing serotypes #; RC2, control reference case; RC2noRestarts, RC2 without restart option; RC2*, WPV1 eradication reference case; T0, beginning of analytical time horizon (i.e., January 1, 2019); Tend, end of analytical time horizon (i.e., December 31, 2029); tOPV, trivalent OPV; tOPVRISIA, 1 dose of IPV in 2019–2023 followed by tOPV use only from January 1, 2024 with pSIAs; tOPVRI, 1 dose of IPV in 2019–2023 followed by tOPV use only from January 1, 2024 without pSIAs; UMI, upper middle-income; US$2019, 2019 US dollars; 1IPV2025, 1 dose of IPV in 2019–2029; 2IPV2025, 1 dose of IPV in 2019–2024 followed by 2 doses of IPV from January 1, 2025.